Table 3

Association between XRCC1 Arg399Gln polymorphism and breast cancer risk stratified by selected hormone-related factors and blood hormone levelsa

Arg/ArgArg/GlnGln/Gln
Case/controlORCase/controlOR (95% CI)Case/controlOR (95% CI)
Years of menstruation
 <Median217/2961.00 (ref)b190/2381.02 (0.78–1.34)44/391.57 (0.96–2.57)
 ≥Median344/3141.00 (ref)252/2600.87 (0.69–1.10)41/351.06 (0.66–1.72)
Waist to hip ratio
 <0.84403/4791.00 (ref)328/3830.96 (0.78–1.18)68/681.16 (0.80–1.68)
 ≥0.8457/1311.00 (ref)113/1140.87 (0.60–1.26)17/62.48 (0.92–6.66)
Body mass index (weight/height2)
 <25387/4511.00 (ref)298/3580.92 (0.74–1.13)68/571.36 (0.93–2.01)
 ≥25173/1591.00 (ref)143/1390.88 (0.63–1.22)17/170.92 (0.44–1.91)
Among postmenopausal women
 Body mass index (weight/height2)
  <25111/1541.00 (ref)74/971.06 (0.71–1.57)17/161.50 (0.72–3.15)
  ≥2577/881.00 (ref)73/611.38 (0.85–2.22)7/80.85 (0.28–2.58)
 Estradiolc
  <Median36/1111.00 (ref)42/791.56 (0.91–2.69)4/120.88 (0.26–2.96)
  ≥Median60/1201.00 (ref)37/740.98 (0.59–1.65)9/111.68 (0.62–4.54)
 Estronec
  <Median34/1071.00 (ref)31/731.38 (0.76–2.51)6/91.85 (0.58–5.90)
  ≥Median61/1221.00 (ref)48/791.13 (0.70–1.84)7/141.10 (0.41–2.95)
 Estrone sulfac
  <Median44/1231.00 (ref)27/721.03 (0.58–1.85)4/81.45 (0.40–5.33)
  ≥Median52/1081.00 (ref)51/811.31 (0.79–2.16)9/151.42 (0.56–3.63)
 SHBGc
  <Median55/1151.00 (ref)48/691.50 (0.90–2.50)4/140.60 (0.18–1.97)
  ≥Median42/1161.00 (ref)32/841.12 (0.65–1.95)9/93.27 (1.16–9.20)
  • a Adjusted for age.

  • b Ref, reference; SHBG, sex hormone-binding globulin.

  • c Among 190 postmenopausal breast cancer patients who had donated a pretreatment blood sample and 407 postmenopausal controls.